Avenue Therapeutics, Inc. (ATXI) Cash Flow Statement
Where ATXI’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$1.8M
- Capital expenditures
- $0 0.0% of revenue
- Free cash flow
- −$1.8M −130.6% margin
- Returned to shareholders
- $4,000
- Change in cash
- $261,000 cash at year-end $2.9M
Drawn to scale: where the cash came from and how it was used. Hover for values.
ATXI operating cash flow, capex and free cash flow
ATXI cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$1.6M2016 | −$1.8M2025 | — | |
| Capital expenditures | $02016 | $02025 | — | |
| Free cash flow | −$1.6M2016 | −$1.8M2025 | — | |
| Stock-based compensation | $28,0002016 | $665,0002025 | +42.2%/yr | |
| Share buybacks (net) | $02016 | $4,0002025 | — |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
ATXI cash flow by activity
ATXI net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
ATXI cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$2.9M | −$11.7M | −$10.4M | −$3.6M | −$3.7M | −$5.2M | −$25.9M | −$21.5M | −$12.3M | −$3.2M |
| Depreciation & amortization | — | — | $14.5M | — | $3.7M | — | — | $21.8M | $174,000 | $2.4M |
| Stock-based compensation | $665,000 | $1.2M | $906,000 | $649,000 | $442,000 | $710,000 | $1.8M | $1.5M | $604,000 | $28,000 |
| Change in working capital | $300,000 | $179,000 | −$290,000 | $408,000 | −$461,000 | −$172,000 | −$2.3M | $1.8M | $2.1M | $1.1M |
| Other non-cash items | $111,000 | $1.3M | −$14.2M | −$5.0M | −$3.7M | $0 | $61,000 | −$21.8M | $2.6M | −$1.9M |
| Cash from operating activities | −$1.8M | −$9.0M | −$9.5M | −$7.6M | −$3.8M | −$4.6M | −$26.3M | −$18.2M | −$6.8M | −$1.6M |
| Investing activities | ||||||||||
| Capital expenditures | $0 | $0 | −$3.0M | $0 | $0 | −$1.0M | $0 | $0 | $0 | $0 |
| Investments (net) | — | $0 | −$3.0M | $0 | $0 | −$1.0M | $0 | $10.0M | −$10.0M | $0 |
| Acquisitions & other investing | — | — | $3.0M | — | — | $1.0M | −$1.0M | $0 | $0 | −$10.0M |
| Cash from investing activities | — | — | −$3.0M | — | — | −$1.0M | −$1.0M | $10.0M | −$10.0M | −$10.0M |
| Financing activities | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | — |
| Share repurchases & issuance (net) | −$4,000 | — | $1.2M | −$1.1M | $0 | — | $32.3M | −$895,000 | $35.0M | $38.0M |
| Net borrowing (repayment) | — | — | — | — | — | — | — | — | −$5.8M | $1.9M |
| Shares issued | $2.1M | $1.6M | $7.5M | $12.0M | $5.0M | $0 | $35.0M | $0 | $0 | $0 |
| Other financing | $4,000 | $8.2M | −$1.2M | −$360,000 | −$663,000 | $4.4M | −$35.0M | $0 | −$715,000 | −$38.0M |
| Cash from financing activities | $2.1M | $9.8M | $7.5M | $10.5M | $4.4M | $4.4M | $32.3M | −$895,000 | $28.4M | $1.8M |
| Summary | ||||||||||
| Net change in cash | $261,000 | $811,000 | −$4.9M | $2.9M | $631,000 | −$5.6M | $6.1M | −$9.1M | $11.6M | $183,000 |
| Cash at end of period | $2.9M | $2.6M | $1.8M | $6.7M | $3.8M | $3.1M | $8.7M | $2.7M | $11.8M | $197,000 |
| Free cash flow | −$1.8M | −$9.0M | −$12.5M | −$7.6M | −$3.8M | −$5.6M | −$26.3M | −$18.2M | −$6.8M | −$1.6M |
| Free cash flow margin | −130.6% | — | — | — | — | — | — | — | — | — |
| Capex / revenue | 0.0% | — | — | — | — | — | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$690,000 | −$695,000 | −$682,000 | −$683,000 | $329,000 | −$1.9M | −$1.6M | −$3.1M | −$2.7M | −$4.3M | $617,000 | $513,000 |
| Depreciation & amortization | — | — | — | — | — | — | — | $3.2M | $2.8M | $3.7M | $2.1M | — |
| Stock-based compensation | $61,000 | $61,000 | $142,000 | $163,000 | $175,000 | $185,000 | $522,000 | $331,000 | $192,000 | $191,000 | $307,000 | $561,000 |
| Change in working capital | $17,000 | $25,000 | −$60,000 | $819,000 | −$675,000 | $447,000 | −$194,000 | −$129,000 | $162,000 | $340,000 | −$911,000 | −$391,000 |
| Other non-cash items | $137,000 | $171,000 | −$254,000 | $84,000 | −$5,000 | $40,000 | $467,000 | −$3.2M | −$2.7M | −$3.0M | −$4.5M | −$1.6M |
| Cash from operating activities | −$475,000 | −$438,000 | −$854,000 | $383,000 | −$176,000 | −$1.2M | −$764,000 | −$2.9M | −$2.3M | −$3.1M | −$2.3M | −$889,000 |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | −$3.0M | −$1.0M |
| Investments (net) | — | — | — | — | — | — | $0 | $0 | — | — | $0 | −$1.0M |
| Acquisitions & other investing | — | — | — | — | — | — | — | — | — | — | $6.0M | $1.0M |
| Cash from investing activities | — | — | — | — | — | — | — | — | — | — | $3.0M | −$1.0M |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | — | — | — | — | −$4,000 | — | — | — | — | — | — | — |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $2.1M | $761,000 | $567,000 | $295,000 | $0 | $3.9M | $550,000 |
| Other financing | $0 | $0 | $0 | $0 | $4,000 | $0 | $0 | $0 | $3.7M | $4.5M | $72,000 | −$71,000 |
| Cash from financing activities | $0 | $0 | $0 | $0 | $0 | $2.1M | $761,000 | $567,000 | $4.0M | $4.5M | $3.9M | $479,000 |
| Summary | ||||||||||||
| Net change in cash | −$475,000 | −$438,000 | −$854,000 | $383,000 | −$176,000 | $908,000 | −$3,000 | −$2.3M | $1.7M | $1.4M | $1.6M | −$1.4M |
| Cash at end of period | $1.9M | $2.4M | $2.9M | $3.7M | $3.3M | $3.5M | $2.6M | $2.6M | $4.9M | $3.2M | $1.8M | $161,000 |
| Free cash flow | −$475,000 | −$438,000 | −$854,000 | $383,000 | −$176,000 | −$1.2M | −$764,000 | −$2.9M | −$2.3M | −$3.1M | −$2.3M | −$1.9M |
| Free cash flow margin | — | — | — | — | −12.5% | — | — | — | — | — | — | — |
| Capex / revenue | — | — | — | — | 0.0% | — | — | — | — | — | — | — |
| Operating cash flow / net income | — | — | — | — | −0.53 | — | — | — | — | — | −3.77 | −1.73 |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
ATXI cash generation
In fiscal 2025 (ended December 31, 2025), Avenue Therapeutics generated -$1.8 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$1.8 million, −130.6% of revenue. It returned $0.0 million to shareholders through dividends ($0) and net share buybacks ($0.0 million). Cash and equivalents rose by $0.3 million over the year.
Related: ATXI income statement, ATXI balance sheet. See the ATXI stock overview for the latest quote and news.
ATXI cash flow FAQ
What is Avenue Therapeutics's free cash flow?
Avenue Therapeutics's free cash flow was -$1.8 million in fiscal 2025: -$1.8 million of operating cash flow minus $0 of capital expenditures It was -$9.0 million a year earlier..
How much cash does Avenue Therapeutics generate from operations?
Avenue Therapeutics generated -$1.8 million of cash from operating activities in fiscal 2025.
How much stock does Avenue Therapeutics buy back?
Avenue Therapeutics spent $0.0 million on net share repurchases in fiscal 2025.